A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder
| Autor: | Matthieu Gratton, Eboo Versi, Raphaëlle Brière, Patrick O. Richard, Le Mai Tu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Urology Urinary Bladder 030232 urology & nephrology Urinary incontinence 03 medical and health sciences 0302 clinical medicine Refractory medicine Humans Prospective Studies Prospective cohort study Aged Denervation Urinary bladder Urinary Bladder Overactive business.industry Significant difference Middle Aged medicine.disease Treatment Outcome medicine.anatomical_structure Overactive bladder 030220 oncology & carcinogenesis Urologic Surgical Procedures Female medicine.symptom business Group outcomes |
| Zdroj: | Urology. 136:88-94 |
| ISSN: | 0090-4295 |
| Popis: | Objective To determine whether the presence of detrusor overactivity (DO) is associated with the 12-week and 12-month clinical outcomes of selective bladder denervation (SBD) in women with refractory overactive bladder (OAB). Methods Prospective single institutional study of refractory OAB females who underwent a urodynamic study and were categorized according to DO status (DO− vs DO+) prior to receiving SBD. Results Among the 23 patients, 10 were DO− and 13 were DO+. Both groups reported improvement at 12 weeks on the 24-hour pad weight test, in urgency urinary incontinence (UUI) and urgency. At 12 months, both groups still reported improvement in urgency, but only the DO− group reported reduction on the pad weight test and only the DO+ group maintained improvement in the UUI rate. Clinical success (≥50% reduction in UUI) was achieved by all DO− and by 69% of DO+ patients at 12 weeks, and by 60% of DO− and 92% of DO+ patients at 12 months. Treatment benefit (Treatment Benefit Scale ≤2) was reported in 90% of DO− and 85% of DO+ patients at 12 weeks, and in 60% of DO− and 85% of DO+ patients at 12 months. When directly comparing both group outcomes, the only significant difference was the greater reduction of UUI in the DO− group at 12 weeks (−9.0 vs −6.5; P = .045). Conclusion Refractory OAB females appear to be effectively treated by SBD regardless of baseline DO status. DO status does not seem to be associated with the 12-week and 12-month outcomes of SBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect